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Abstract: This study analyzed the possible interaction effects between tobacco consumption and
anxiety or depression during pregnancy on maternal and neonatal health. We recruited a sample of
807 pregnant Spanish women from public healthcare services. Women completed a questionnaire
on sociodemographic variables, health status and tobacco consumption (continuous, quitting or
no consumption) in the first and third trimester of pregnancy and at 2 months postpartum,
and self-reported measures of anxiety and depression in the first trimester. Abstinence of tobacco
consumption was verified through biochemical measurements. Interaction effects between tobacco
consumption and anxiety were found for delivery (p < 0.001), neonatal health complications (p = 0.026)
and gestational age at birth (p = 0.029). Interaction effects between tobacco consumption and depression
were found for pregnancy (p = 0.032), delivery complications (p < 0.001) and weeks of gestation
at birth (p = 0.031). This study suggests that there are different kinds of interaction effects between
tobacco consumption and anxiety or depression. Smokers with high anxiety presented more delivery
complications compared to quitters and non-smokers with high anxiety. There is a cumulative
effect of anxiety on the effects of tobacco consumption on maternal health. The results highlighted
the beneficial impact of quitting smoking during pregnancy to reduce the risk of suffering anxiety,
depression and health complications.
Keywords: tobacco consumption; anxiety; depression; pregnancy complications; delivery complications;
neonate’s health problems; low birth weight
1. Introduction
Maternal tobacco consumption during pregnancy has been linked with several maternal
and infant health complications. Particularly, maternal tobacco consumption during pregnancy
was associated with an increased risk of placental pathologies, such as ruptures or premature
detachment of the membranes [1], placenta previa [2–4], ectopic pregnancy [5–7] and miscarriage [8,9].
Tobacco consumption during pregnancy is also a risk factor for neonatal health. Premature birth [10,11]
and low birth weight are usually present, as the neonates of mothers who smoked during pregnancy
weigh approximately 150–250 g less than those of non-smoking mothers [12]. Additionally, the risk
of intrauterine growth restriction, fetal death, perinatal mortality (e.g., sudden death syndrome and
respiratory distress syndrome), malformations and developmental delays is also increased in the
neonates of mothers who smoked during pregnancy [11,13,14].
Anxiety and/or depression during pregnancy were associated with maternal and infant health
complications that were similar to those produced by tobacco consumption, including preeclampsia,
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fetal distress, forceps delivery and prolonged or preterm labor [15–18]. High levels of maternal
anxiety or depression during pregnancy were also associated with neonatal health [19–21],
specifically preterm birth and low birth weight [21–25]. As stated by [19], anxiety and depression
influence obstetric outcomes.
Anxiety and/or depression have been related to tobacco consumption and smoking cessation in
distinct populations, including pregnant women [26–30]. Higher levels of anxiety and/or depression
were found in pregnant women who smoke [28,30–33]. Likewise, a recent review found that
psychological factors play an important role in smoking cessation, and not suffering from depression is
one of the major predictors of quitting during pregnancy [34].
Despite the strong association between tobacco consumption and anxiety or depression
during pregnancy, these factors have been concurrently considered a small number of times when their
effects on maternal and neonatal health were studied. Few studies have focused on examining the
joint effect of maternal tobacco consumption and anxiety or depression during pregnancy, and results
are somewhat controversial. Regarding depression, although Schechter et al. [35] found that exposure
to tobacco consumption has a higher negative effect on the neonate’s birth weight of mothers with
co-occurring depression symptoms, no significant cumulative effect on the mother’s depression
in the effect of smoking during pregnancy was found on premature birth or low birth weight by
Quispel et al. [36]. Regarding anxiety, a strong relationship has been independently found between
anxiety and smoking and premature birth [37,38]. However, to our knowledge, the only study
that evaluated the simultaneous effect of maternal anxiety and tobacco consumption on pregnancy
complications showed controversial results, and no significant effect was found between tobacco
consumption and pregnancy complications [39].
In sum, tobacco consumption and anxiety or depression have been concurrently considered few
times when effects were studied on maternal and neonatal health, despite their similar effects and
strong associations.
It is also worth pointing out that most of the studies that evaluate the consequences of smoking
during pregnancy on maternal and neonatal health focused on comparing non-smokers and smokers,
leaving aside the possible effect of quitting smoking during pregnancy, and the few studies that
evaluate this effect focus on the neonate’s weight [40,41]. To analyze the effects of quitting smoking on
other aspects of maternal and neonatal health can be particularly relevant to promoting more effective
health practices, specifically to the decision of health professionals to advise women to reduce or quit
smoking during pregnancy, and to motivate pregnant women to quit smoking.
Taking this into consideration, this study aims to analyze the possible interaction effects
between tobacco consumption during pregnancy (continuous, quitting and no consumption)
and maternal anxiety or depression in the first trimester of pregnancy on maternal and neonatal health
(pregnancy complications, delivery complications, neonatal health complications, gestational age and
birth weight).
2. Materials and Methods
2.1. Procedure and Participants
The present research was conducted in accordance with the Helsinki Declaration and received
previous approval from the Ethical Commission of all institutions involved (Ethical Board consent
number 2010/299). This is a longitudinal study with three assessment waves: first trimester of pregnancy
(M = 9.94 weeks; SD = 4.22), third trimester of pregnancy (M = 33.28 weeks; SD = 2.05), and 2 months
postpartum (M = 7.39 weeks; SD = 0.86). Pregnant women attending primary public healthcare services in
the northwest of Spain were recruited in the first trimester of pregnancy (N = 901). Women were eligible to
participate if they were at least 18 years of age, were in the first trimester of pregnancy and spoke Spanish.
The aims and procedures were explained and pregnant women who were willing to participate
provided written informed consent. Two trained psychologists conducted the interviews individually.
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Women completed a questionnaire on socio-demographic variables, health status, and tobacco
consumption, and self-reported measures of anxiety and depression. Maternal anxiety and depression
and tobacco consumption status (continuous, quitting or no consumption) were considered in the
first trimester of pregnancy, in accordance with recent evidence in the literature indicating that the
major adverse effects on fetus health and development may occur in the first trimester of gestation [5].
The first trimester is also the moment in which pregnant women usually decide to quit smoking [28,42].
Tobacco consumption was assessed in the three assessment waves by self-reported and biochemical
tests. In the first trimester, socio-demographic data were also collected, while health variables related
to pregnancy were evaluated in the third trimester. Information regarding delivery and the neonate’s
health was collected at 2 months postpartum.
The sample comprises 807 pregnant women (see Figure 1). From the 901 pregnant women
recruited in the first trimester of pregnancy, 94 women were lost (10.4%) at 2 months postpartum:
28 had suffered a miscarriage, 29 could not be contacted, 4 refused to continue participating in the
study and 33 pregnant women were excluded (23 women for changing consumption status after first
trimester of pregnancy and 10 for consuming other substances).
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2.2. Measures
2.2.1. Socio-Demographic, Health and Tobacco Consumption Information
A questionnaire was used to collect information regarding socio-demographic and
pregnancy-related aspects, consumption information, pregnancy and delivery complications
(e.g., threat of abortion, placental problems, threat of premature birth, hemorrhage, fetal suffering),
neonate’s health problems (e.g., respiratory problems), gestational age at birth and birth weight.
2.2.2. Consumption Status
Pregnant women were classified into three groups based on their self-report of tobacco
consumption and the result of the biochemical test: continuous smokers, continuous quitters and
non-smokers. Women who maintained their consumption throughout the pregnancy were classified
as continuous smokers. Women who reported quitting when they expected or confirmed they were
pregnant and who maintained abstinence during pregnancy were classified as continuous quitters.
Women who reported no smoking in the past or who reported quitting at least one year before they
became pregnant were classified as non-smokers. In the first evaluation, pregnant women were asked if
they had ever been smokers and if they had smoked before pregnancy. If the answer was yes, they were
requested to indicate the number of cigarettes per day they smoked before pregnancy; if the answer
was negative, they were requested to report how long they had gone without smoking. At all times of
the evaluation, they were asked what was their current situation in relation to tobacco consumption
using multiple answer options: never smoker, currently I do not smoke and I have quit during pregnancy,
I am an occasional smoker or I am a daily smoker. At the postpartum evaluation, an alternative answer
was added: I quit smoking during pregnancy but started smoking again. Likewise, at all times, it was
requested that those who indicated that they had quit smoking, specified in which month they quit,
and those women who defined themselves as smokers, indicated the number of cigarettes they smoked.
Because the aim of the study was the effects of tobacco consumption status (continuous, quitting or
no consumption) during pregnancy on maternal and neonatal health, women reporting changes in their
consumption status after the first trimester of pregnancy (n = 23) were not included in the analyses.
Self-reports of smoking abstinence were biochemically verified through urinary cotinine by
Cotinine Test Medi-marketing (cut-off 200 ng/mL) in the first trimester and through carbon monoxide
(CO) in expired air in the third trimester and at 2 months postpartum (cut-off of 5 ppm) using a Carbon
Monoxide Monitor (model Smokerlyzer Pico Simple; Bedfont Technical Instruments Ltd., Kent, UK).
2.2.3. Anxiety
The State Anxiety Scale (STAI-S) of the State–Trait Anxiety Inventory [43] was used to assess
women’s anxiety in the first trimester of pregnancy. The STAI-S consists of a 20-item scale designed to
assess the current state of anxiety. The score ranges from 0 to 60 and higher scores indicate higher
anxiety symptoms. The STAI-S Spanish version showed good internal consistency and proposed
a clinical cut-off >31 to screen for high-anxiety in women. In the present study, the STAI-S showed
excellent internal consistency (α = 0.94).
2.2.4. Depression
The Edinburgh Postnatal Depression Scale (EPDS) was used to assess women’s depression in
the first trimester of pregnancy. The EPDS is a 10-item self-reported questionnaire designed to assess
the intensity of depression symptoms within the previous 7 days [44]. The EPDS is the most widely
used questionnaire to screen pregnancy and postpartum depression symptoms [28,45]. The EPDS
Spanish version showed good internal consistency [46]. In the present study, the EPDS showed good
internal consistency (α = 0.85).
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2.3. Data Analysis
Chi-square tests were performed to analyze the associations and the interaction effects
between tobacco consumption status, anxiety or depression on pregnancy, delivery and neonatal
health complications (dichotomic dependent variables). The MANCOVA was performed to analyze the
interaction effects between tobacco consumption status, anxiety or depression (independent variables)
on gestational age and birth weight (continuous dependent variables). The sociodemographic
variables associated with the independent variables (marital status, parity, educational level and
previous consumption) were included in the models as covariates. Pairwise comparisons were applied
to assess within-group differences.
Data were analyzed with IBM SPSS 23.0 Windows version (PASW Statistics for Windows, SPSS Inc.,
Chicago, IL, USA). Statistical significance level was considered at p < 0.05.
3. Results
3.1. Participant Sociodemographic Characteristics
Participants’ age ranged between 18 and 46 years old (M = 32.74 years; SD = 4.35) and most were
married or cohabiting (83.8%). More than half had university studies (53.4%) and were employed (70.9%).
In this sample, 28% smoked before pregnancy and their average of previous consumption was 10.88
(SD = 6.98). Most of the infants were the firstborn (65.9%), and were born with 37 weeks or more (96.0%)
and with a normal weight (94.4%; M = 3274.99 g; SD = 547.50).
3.2. Associations between Tobacco Consumption, Anxiety or Depression, and Sociodemographic Characteristics
Significant associations were found between maternal tobacco consumption status and marital status,
parity, educational level, professional status, and socioeconomic level. Significant associations were
also found between maternal depression and educational level and between maternal anxiety and
marital status (see Table 1).
3.3. Associations between Tobacco Consumption and Anxiety or Depression
Maternal tobacco consumption status was associated with anxiety (χ2 = 15.18, p = 0.001, Cramer’s
V = 0.14) and depression (χ2 = 12.87, p = 0.002, Cramer’s V = 0.13) in the first trimester of pregnancy.
Continuous smokers during pregnancy were more likely to present high anxiety (14.8% vs. 8.2%
vs. 5.2%) and depression (18.8% vs. 9.2% vs. 8.3%) than continuous quitters and non-smokers.
No significant differences were found between continuous quitters and non-smokers during pregnancy
in the rates of high anxiety (Z = 0.3, p = 0.748) and depression (Z = 0.1, p = 0.929).
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Table 1. Maternal socio-demographic characteristics, consumption status, anxiety and depression.
Socio-Demographic
Characteristics

























1.56 0.10 0.6418–34 63.3 64.8 68.4 62.1 61.4 63.5 59.3 63.8








Single/divorced 16.2 24.2 17.3 14.3 29.8 15.2 34.6 14.2
Married/living with




0.56 3.34Primiparous 65.9 68.0 79.6 63.2 61.4 66.3 56.8 66.9







years) 46.6 75.8 50.0 39.6 54.4 46.0 60.5 45.0
University




0.39Unemployed 29.1 39.1 26.5 27.4 31.6 28.9
0.18
32.1 28.8




0.98 0.01Medium-low 62.8 73.5 70.1 59.6 69.2 62.3 64.4 62.7
Medium-high 37.2 26.5 29.9 40.4 30.8 37.7 35.6 37.3
* p < 0.05; *** p < 0.001.
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3.4. Associations between Tobacco Consumption, Anxiety or Depression, and the Mother’s and the
Neonate’s Health
Maternal tobacco consumption status was associated with pregnancy (p = 0.014, Cramer’s V = 0.10)
and delivery (p < 0.001, Cramer’s V = 0.21) complications and neonatal health complications (p = 0.025,
Cramer’s V = 0.10). Continuous smokers during pregnancy were more likely to present pregnancy and
delivery complications, and their neonates to present health complications than continuous quitters and
non-smokers. No significant differences were found between continuous quitters and non-smokers on
the rates of pregnancy (Z = 0.3, p = 0.781) and delivery (Z = 0.5, p = 0.583) complications, and neonatal
health (Z = 0.5, p = 0.645) complications (see Table 2).
Significant differences were found in neonatal birth weight in accordance with maternal tobacco
consumption status (F(804) = 5.53, p = 0.004). Neonates of continuous smokers were born with lower
weight than neonates of continuous quitters (p = 0.049) and neonates of non-smokers (p = 0.003), with no
significant differences between the weight of neonates born to continuous quitters and non-smokers
(3128.36 vs. 3294.39 vs. 3304.03). However, no significant differences were found in gestational age in
accordance with tobacco consumption (F(804) = 5.53, p = 0.315).
Regarding maternal anxiety and depression in the first trimester of pregnancy, high anxiety
was associated with more delivery complications (p = 0.040, Cramer’s V = 0.07) and depression was
associated with more pregnancy complications (p = 0.034, Cramer’s V = 0.08).
Significant differences were found in the neonate’s weeks of gestation at birth in accordance
with the mother’s anxiety (t(805) = 2.52, p = 0.012) and the mother’s depression in the first trimester
(t(805) = 1.35, p = 0.045). Neonates of high anxiety or depressed mothers were born with less weeks of
gestation than neonates of low anxiety or non-depressed mothers. No differences were found in birth
weight according to the mother’s anxiety (t(805) = 0.37, p = 0.713) or depression (t(805) = 0.70, p = 0.484)
in the first trimester of pregnancy.
3.5. Interaction Effects between Tobacco Consumption Status and Anxiety or Depression on the Health of
Mothers and Neonates
No significant interaction effects between maternal tobacco consumption status and anxiety were
observed for pregnancy complications (χ2 = 9.31; p = 0.097).
Significant interaction effects between maternal tobacco consumption status and anxiety were
observed for delivery complications (see Table 3). Continuous smokers with high anxiety (group 1)
had more delivery complications than any other group (groups 2, 3, 4, 5 and 6). Continuous smokers
with low anxiety (group 2) had more delivery complications than non-smokers with low anxiety
(group 6). Both, continuous smokers with low anxiety (group 2) and continuous quitters with high or
low anxiety (groups 3 and 4), had more delivery complications than non-smokers with high anxiety
(group 5).
Significant interaction effects between maternal tobacco consumption status and anxiety were
also observed for neonatal health complications. Neonates of continuous smokers with high anxiety
(group 1) had more health complications than neonates of non-smokers, regardless of their level
of anxiety (groups 5 and 6).
Significant interaction effects between maternal tobacco consumption status and anxiety were
observed for gestational age at birth (see Table 4). Neonates of continuous smokers with high anxiety
(group 1) were born after less gestational weeks than neonates of non-smokers with low anxiety
(group 6). No significant interaction effect between maternal tobacco consumption status and anxiety
were observed for birth weight (F(802) = 0.30, p = 0.596).
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Table 2. Association between consumption status, anxiety or depression, and health complications.
Health
Complications













2 Depression NoDepression χ
2 Total
Pregnancy
complications 21.1 9.2 12.4
8.55




complications 27.3 13.3 8.3
36.64
*** 1 > 2,3 19.3 11.3
3.2
* 9.9 12.1 0.35 11.9
Neonatal health
complications 12.5 10.2 6.0
7.41
* 1 > 3 7.0 7.6 0.03 6.2 7.7 0.25 7.6
* p < 0.05; *** p < 0.001.
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Table 3. Interaction effects between consumption status and anxiety or depression on health complications.
Health
Complications
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Delivery

































complications 25.0 20.2 22.2 9.0 20.8 11.6 12.18 * 2 > 4,6
Delivery




complications 8.3 13.5 11.1 11.2 8.3 6.0 9.63
* p < 0.05; *** p < 0.001.
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Table 4. Interaction of consumption status and anxiety or depression on weeks and weight at birth.

































38.48 39.34 38.25 39.37 39.27 39.43
6.90 * 1 < 6(3.37) (1.34) (1.91) (1.41) (1.23) (1.50)
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6.21 * 1 < 6(1.17) (1.95) (1.95) (1.40) (1.32) (1.50)
Birth weight 3075.77 3138.68 3321.00 3287.28 3299.58 3304.75 1.08(485.40) (472.15) (490.04) (545.49) (575.96) (556.40)
* p < 0.05.
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Significant interaction effects between maternal tobacco consumption status and depression
were observed for pregnancy complications (see Table 3). Non-depressed continuous smokers
(group 2) had more pregnancy complications than non-depressed continuous quitters (group 4)
and non-depressed non-smokers (group 6).
Significant interaction effects between maternal tobacco consumption status and depression were
observed for delivery complications. Depressed continuous smokers (group 1) had more delivery
complications than depressed (group 5) and non-depressed (group 6) non-smokers. Non-depressed
continuous quitters (group 4) had more delivery complications than depressed non-smokers (group 5).
No significant interaction effects between maternal tobacco consumption status and depression were
observed for neonatal health complications (χ2 = 9.63; p = 0.087).
Likewise, significant interaction effects between maternal tobacco consumption status and
depression were observed for weeks of gestation at birth (see Table 4). Neonates of depressed
continuous smokers (group 1) were born after less gestational weeks than neonates of non-depressed
non-smokers (group 6). No significant interaction effects between maternal tobacco consumption
status and depression were found on birth weight (F(802) = 1.08, p = 0.398).
4. Discussion
This study aimed to analyze the possible interaction effects between tobacco consumption during
pregnancy and maternal anxiety or depression in the first trimester of pregnancy on the health of
mothers and newborns. An association between maternal tobacco consumption and anxiety or
depression in the first trimester of pregnancy was found. Maternal tobacco consumption status was
associated with high anxiety as well as with depression, as previously noted in the literature [28,30–33].
Continuous smokers were more likely to present high anxiety and depression than continuous quitters
and non-smokers in the first trimester of pregnancy. On the other hand, no significant differences were
found between continuous quitters and non-smokers on rates of anxiety or depression. These results
highlighted the possible beneficial impact of quitting smoking during pregnancy for the prenatal
mental health of mothers.
An independent effect of maternal tobacco consumption, anxiety and depression during pregnancy
on the health of mothers and neonates was found. Maternal tobacco consumption during pregnancy
was associated with more pregnancy and delivery and neonatal complications, including low
birth weight. Interestingly, maternal anxiety in the first trimester of pregnancy was associated
with delivery complications, while maternal depression in the first trimester of pregnancy was
associated with pregnancy complications.
Several studies have shown that tobacco consumption during pregnancy directly affects the health
of both mothers and neonates throughout the perinatal period [2–9,47,48]. Tobacco consumption
during pregnancy can lead to epigenetic changes that affect the health of mothers and neonates. One of
the main mechanisms is through the impact of tobacco carbon monoxide. This component of tobacco
can cause defective vascularization, placental hypertrophy and/or local hypoxia, which reduces uterine
blood flow, increasing the risk of complications and restricting fetal growth [3]. Another important
action mechanism is the effect of nicotine on the organism. This component has a vasoconstrictor
effect and has also been related to the activation of the enzyme phospholipase A2, which is associated
with undergoing abortions. However, during the postpartum period, the effects of tobacco on
health do not exclusively affect the mother, as the nicotine can be transferred to the neonate through
breast milk [11]. These data emphasize the negative effect of tobacco consumption on the course
of pregnancy. Contrarily, no significant differences were found between continuous quitters and
non-smokers on the studied maternal health complications, neither on neonatal weight at birth nor
health complications. These results suggest that early and continued tobacco quitting during pregnancy
could decrease maternal risks of suffering health problems during this period of life [40,41]. It should
be noted that results (56.6% of women continue to smoke during pregnancy) indicate higher prevalence
of smoking than other research carried out in Spain previously (27–42%) [49,50], although similar
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to the data provided by studies carried out in Europe (57–65%) [51,52]. These differences between
prevalence may be due to the methodologies used. Spanish studies are retrospective and based
on self-reports (methodology susceptible to bias due to social desirability), whereas the European
ones are prospective and use biochemical validation of consumption. As with tobacco consumption,
several studies have shown that maternal anxiety and/or depression negatively affect the health of both
mothers and neonate throughout the perinatal period [15–18]. This study added that maternal anxiety
and depression are specifically associated with different health complications and at different times.
Maternal anxiety was found to be associated with complications related to delivery, while maternal
depression seems to affect health complications arising during pregnancy. These results contribute
to clarify the potential differential impact of maternal anxiety and depression on pregnancy and
delivery complications, an issue that remained unclear in the literature [19]. Different underlying
epigenetic and endophenotypic mechanisms were suggested to explain the effect of maternal anxiety
and/or depression on the emergence of different types of complications. Several studies pointed out that
the presence of anxiety or depression can be a stressor for pregnant women, stimulating the activation
of different mechanisms, namely the hypothalamic axis (HPA), affecting the course of pregnancy [15,53].
Likewise, it could also affect the physiological development of the newborn by interfering with the
levels of cortisol, norepinephrine and dopamine [16]. Experiencing high levels of anxiety or depression
during pregnancy may contribute to an increase in hormones such as cortisol and catecholamines,
which cause changes in immunologic functioning and uterine blood flow during human pregnancy,
thus increasing vulnerability [18].
The results of the interaction effect between maternal consumption status and anxiety or depression
suggested that different kinds of interactions were also found. Specifically, three different kinds of
interactions were found. First, an interaction in which the fundamental role is of tobacco consumption,
such as the results of the interaction effect between maternal consumption status and anxiety or
depression on delivery complications. Second, an interaction in which the fundamental role is
developed by anxiety or depression. Regarding neonatal health problems, the results of the interaction
effect between maternal consumption status and anxiety or depression suggested that effects of tobacco
consumption on the gestational age of neonates at birth only emerged when maternal consumption
status was associated with anxiety or depression, as no independent effects of maternal consumption
status were found. The neonates of continuous smokers with high anxiety or depression were born
with fewer weeks than the neonates of non-smokers with no anxiety or no depression.
Finally, an interaction that suggested a cumulative effect of maternal anxiety in the first trimester
of pregnancy on the effects of tobacco consumption status (continuous, quitting and no consumption)
during pregnancy on the mother’s health was also found. Continuous smokers with high-anxiety
presented more delivery complications than continuous smokers with low-anxiety. This effect could be
explained by the simultaneous activation of the mechanisms activated by tobacco consumption [3,11]
and those activated due to the presence of anxiety [15–18]. However, no cumulative effects of anxiety
or depression were found on pregnancy complications. This result suggested that the effect of maternal
tobacco consumption can be so adverse that anxiety and depression did not increase the risks of
pregnancy complications.
Altogether, these data highlighted the close relationship between tobacco consumption,
the presence of psychological symptoms (anxiety or depression) and adverse health outcomes [39],
being one of the few studies that jointly assess the effect of maternal tobacco consumption, anxiety or
depression on health during pregnancy.
This study has certain limitations. Although the selected measures are those of international
reference and have shown good internal consistency, anxiety and depression were evaluated
with self-reports, which may imply different biases of social desirability, such as the concealment
of symptoms. Likewise, pregnancy and delivery complications were evaluated dichotomously
(presence or absence of complications), what can lead to bias in the interpretation of results and
which does not allow for an in-depth study of these repercussions. In future studies, it would be
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relevant not only to assess the presence of complications, but also the number, type and severity of
the same. Likewise, the sample was collected exclusively in public healthcare centers, which does
not allow for the generalization of the results to all pregnant women, since women who attend
private healthcare facilities could present different characteristics. Despite these limitations, this study
presents several strengths. This is a longitudinal study that followed a large number of women
during pregnancy and the early postpartum period. This allowed exploring possible interaction
effects between the variables. Moreover, the cumulative effect of anxiety or depression in the effect of
tobacco consumption was studied in different relevant aspects related to maternal and infant health in
pregnancy and the early postpartum. Moreover, self-reports of tobacco abstinence were validated with
biochemical tests. This is particularly relevant in this population due to the social pressure suffered by
women not to smoke [54] and this may suppose that some women hide their consumption [55].
The results of this research have practical implications and could help to improve healthcare
during pregnancy, as they highlight the importance of evaluating both the presence of tobacco
consumption and the level of anxious and depressive symptoms during pregnancy. One of the main
reasons for health professionals not to advise pregnant women to quit tobacco is the consideration that
anxiety can increase after quitting smoking. However, quitting smoking reduces the risk of suffering
anxiety and depression during pregnancy, as well as health risks. These data are proof of how quitting
smoking can be beneficial both for the physical and psychological health of pregnant women as well as
for the newborn itself. Data highlights the importance of advice during the perinatal period focusing
on smoking cessation and not reducing cigarette consumption, since the former would lead to a lower
prevalence of health problems (physical and psychological) in both women as well as their children.
5. Conclusions
This study suggests that there are different kinds of interaction effects between tobacco consumption
and anxiety or depression on the health of mothers. The likelihood of health problems increases when
mothers jointly present tobacco consumption and high anxiety. Specifically, a cumulative effect of
anxiety and tobacco consumption on delivery complications was found. Likewise, a beneficial effect
of quitting smoking was found both on the physical health of newborns and on the physical and
psychological health of women. In particular, quitting smoking during pregnancy reduced the risk of
suffering anxiety, depression and health complications.
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